# Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

> **NCT03232892** · PHASE2 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 1 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03232892
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-13
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-09-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2019-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03232892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03232892, "Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03232892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*